focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPM.L Regulatory News (MPM)

  • There is currently no data for MPM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

16 Jul 2007 11:29

Minster Pharmaceuticals PLC16 July 2007 For immediate release 16 July 2007 MINSTER PHARMACEUTICALS PLC ("Minster" or "the Company") Result of AGM Minster Pharmaceuticals plc (AIM: MPM), the drug development companyspecialising in neurological and psychiatric disorders, held its AGM today atwhich all resolutions were duly passed. - ENDS - For further information: Minster Pharmaceuticals plc Tel: +44 (0) 1799 506623Paul Sharpe, Chief Executive OfficerRobert Aubrey, Chief Financial Officer Buchanan Communications Tel: +44 (0) 20 7466 5000Mark CourtRebecca Skye Dietrich Nomura Code Securities Limited Tel: +44 (0) 20 7776 1200Richard PottsGerard Harper Notes for editors: About Minster Pharmaceuticals plc Minster Pharmaceuticals is a drug development company focussed on neurologicaland psychiatric disorders. Its principal pipeline assets are tonabersat, underdevelopment in the preventive treatment of migraine, and sabcomeline inschizophrenia. Worldwide rights to both compounds were acquired fromGlaxoSmithKline and the compounds benefit from comprehensive safety tolerancedata as a result of investment by GSK. Tonabersat is the most advanced compound in an exciting new class of drugscalled gap junction blockers, which have significant potential in the preventionof migraine and other major neurological conditions. Sabcomeline, a muscarinicpartial agonist, has potential in the treatment of chronic schizophrenia. Minster's near-term focus is on the development and commercialisation of itscurrent pipeline. Its medium term strategy is to leverage the anticipatedcashflows from the current pipeline by in-licensing further compounds with theultimate objective of creating a substantial and highly efficient drugdevelopment enterprise focussed on the central nervous system. Minster joined the AIM market in February 2005 and trades under the symbol MPM.For further information please visit www.minsterpharma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Dec 20057:00 amPRNNotice of Results
30th Nov 20052:35 pmRNSHolding(s) in Company
26th Oct 200511:20 amPRNAGM Statement
25th Oct 20056:00 amPRNRe Agreement
14th Oct 20056:00 amPRNResearch Update
26th Aug 200511:46 amRNSHolding(s) in Company-Replace
25th Aug 20051:50 pmRNSHolding(s) in Company
8th Aug 20053:38 pmRNSHolding(s) in Company
21st Jul 200512:00 pmRNSHolding(s) in Company
12th May 20053:37 pmRNSIssue of Options
28th Apr 20054:36 pmRNSHolding(s) in Company
4th Mar 200512:12 pmRNSConversion of Warrant
3rd Mar 20053:04 pmRNSHolding(s) in Company
21st Feb 200512:13 pmRNSResult of EGM
8th Feb 20053:56 pmRNSLoan Note Conversion
3rd Feb 200511:48 amRNSHolding(s) in Company
1st Feb 20055:42 pmRNSHolding(s) in Company
28th Jan 200512:43 pmRNSHolding(s) in Company
27th Jan 20057:02 amRNSAdmission to AIM
27th Jan 20057:00 amRNSRestoration - RII plc
27th Jan 20057:00 amRNSSch 1 - RII plc
27th Jan 20057:00 amRNSChange of Adviser
17th Jan 20051:00 pmRNSStatement re. Suspension
17th Jan 20051:00 pmRNSSuspension - RII plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.